We are pleased to share the BioCanRx 2024-2025 Annual Report.
This report highlights the remarkable achievements of our network as we successfully navigated a transition in funding while maintaining our momentum. With the launch of our $38 million, five-year commitment from the Strategic Science Fund (SSF), BioCanRx was able to support projects already in our pipeline and invest in new initiatives selected for their high potential to move toward clinical trial. These investments underscore our resilience and our steadfast commitment to ensuring Canadian patients have timely access to innovative cancer therapies developed here at home.
